tbuckley/cabot-search huggingface dataset:
Seasonality in Sudden Infant Death Syndrome
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
Authors: Muhammad Bilal Abid, Micah Rubin, Nathan Ledeboer, Aniko Szabo, Walter Longo, Meera Mohan, Nirav N. Shah, Timothy S. Fenske, Sameem Abedin, Lyndsey Runaas, Anita D’Souza, Saurabh Chhabra, Binod Dhakal, Mehdi Hamadani
Journal: Cancer Cell (2022)
SUCH IS FAME.
Journal: JAMA (1901)

According to the newspaper reports, the president of the New York City Department of Health first heard of Professor Koch and possibly also of the tubercle bacillus when a reporter called upon him to interview him on the sensation of the day. "Who is this man Koch?" was the official's inquiry, and when informed, he said: "Well, I don't know anything about him," and then turned to weightier matters. It is probable, as the newspaper says, that he does not think Professor Koch is half as great a man as he is. With some New York City officeholders the vision is limited to the Tammany jurisdiction and nothing outside of that is worth knowing. The official in this case, however, is, as many of us can testify, not a bad type of a too large class of individuals who get into places in our large cities through political machination and
Reply
Authors: Xinrong Zhang, Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Vincent Wai‐Sun Wong
Journal: Hepatology (2022)

We thank Dr. Panigrahi and colleagues for their comments on our paper. They referred to two review articles and inquired on the reasons for a differential effect between angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin‐receptor blockers on liver‐related outcomes in patients with NAFLD. During the period of the study, a number of angiotensin‐receptor blocker preparations were removed from the market because of possible contamination by carcinogens.[1] In addition, because of the price difference, most patients were initially on ACEIs, only to switch to angiotensin‐receptor blockers when they developed side effects such as coughing. It is therefore difficult to discern the independent effects of angiotensin‐receptor blockers. Data on liver histology or transient elastography were not available in this database. Among the 183 patients without cirrhosis at baseline, 162 had liver cancer, and 26 had cirrhotic complications during follow‐up. Compared with nonusers, patients without cirrhosis who used ACEIs had subdistribution HRs of 0.43 (95% CI 0.26–0.72) and 0.43 (95% CI 0.26–0.71) for liver cancer and cirrhotic complications, respectively. Dr. Panigrahi et al. also discussed the risk of angiotensin‐receptor blockers during pregnancy. Although we do not have information on pregnancy, please note that the mean baseline age of angiotensin‐receptor blocker users was 61.6 years (Table S3 of our paper), so it is unlikely that there were many pregnant women in this cohort. In any case, such interruption would have been transient. Finally, we agree with Dr. Panigrahi et al. that prospective studies, preferably randomized controlled trials, would provide definitive proof for the effect of ACEIs on liver‐related events. Nonetheless, because ACEIs have already become generic and it would take thousands of patients being followed for 5 to 10 years to demonstrate a difference in clinical events, we doubt if such a study will ever materialize. As for mechanistic work, a number of studies have already demonstrated an effect of ACEIs on liver fibrosis and hepatocarcinogenesis.[2,3] In such situations, sometimes the best evidence has to come from adequately powered retrospective studies with a sufficient duration of follow‐up. CONFLICT OF INTEREST Dr. Yip consults for and is on the speakers' bureau for Gilead Sciences. Dr. V. Wong consults for and received grants from Gilead. He consults for AbbVie, Boehringer Ingelheim, Echosens, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, and ProSciento. He is the cofounder of Illumina Medical Technology Limited.
Primary mucosa-associated lymphoid tissue lymphoma of the entire esophagus diagnosed by endoscopic ultrasound-guided fine needle aspiration
Authors: Chaoqun Han, Rong Lin, Mingyao Xu, Jun Liu, Zhen Ding
Journal: Endoscopy (2022)

A 62-year-old woman was admitted for progressive dysphagia and weight loss over a 6-month period. She had no evidence of any abnormal laboratory findings or immunosuppressive diseases. Physical examinations were also unremarkable.
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
Authors: Yan Li, Wen Zhang, Ruichen Zhao, Xin Zhang
Journal: Bioactive Materials (2022)

Peptide drugs play an important role in diabetes mellitus treatment. Oral administration of peptide drugs is a promising strategy for diabetes mellitus because of its convenience and high patient compliance compared to parenteral administration routes. However, there are a series of formidable unfavorable conditions present in the gastrointestinal (GI) tract after oral administration, which result in the low oral bioavailability of these peptide drugs. To overcome these challenges, various nanoparticles (NPs) have been developed to improve the oral absorption of peptide drugs due to their unique in vivo properties and high design flexibility. This review discusses the unfavorable conditions present in the GI tract and provides the corresponding strategies to overcome these challenges. The review provides a comprehensive overview on the NPs that have been constructed for oral peptide drug delivery in diabetes mellitus treatment. Finally, we will discuss the rational application and give some suggestions that can be utilized for the development of oral peptide drug NPs. Our aim is to provide a systemic and comprehensive review of oral peptide drug NPs that can overcome the challenges in GI tract for efficient treatment of diabetes mellitus.
Diphtheria in the WHO European Region, 2010 to 2019
Authors: Mark Muscat, Belete Gebrie, Androulla Efstratiou, Siddhartha S Datta, Danni Daniels
Journal: Eurosurveillance (2022)

BackgroundDiphtheria is uncommon in the World Health Organization (WHO) European Region. Nevertheless, sporadic cases, sometimes fatal, continue to be reported.AimTo report on diphtheria cases and coverage with first and third doses of diphtheria, tetanus and pertussis vaccines (DTP1 and DTP3, respectively) for 2010-19 in the Region with a focus on 2019.MethodsData on diphtheria cases were obtained from WHO/United Nations International Children's Emergency Fund (UNICEF) Joint Reporting Forms submitted annually by the Region's Member States. WHO/UNICEF Estimates of National Immunization Coverage for DTP1 and DTP3 were summarised for 2010-19. For 2019, we analysed data on age, and vaccination status and present data by country on DTP1 and DTP3 coverage and the percentage of districts with ≥ 90% and < 80% DTP3 coverage.ResultsFor 2010-19, 451 diphtheria cases were reported in the Region. DTP1 and DTP3 coverage was 92-96% and 95-97%, respectively. For 2019, 52 cases were reported by 11 of 48 countries that submitted reports (including zero reporting). Thirty-nine countries submitted data on percentage of their districts with ≥ 90% and < 80% DTP3 coverage; 26 had ≥ 90% districts with ≥ 90% coverage while 11 had 1-40% districts with < 80% coverage.ConclusionLong-standing high DTP3 coverage at Regional level probably explains the relatively few diphtheria cases reported in the Region. Suboptimal surveillance systems and inadequate laboratory diagnostic capacity may also be contributing factors. Still, the observed cases are of concern. Attaining high DTP3 coverage in all districts and implementing recommended booster doses are necessary to control diphtheria and prevent outbreaks.
Pediatric Dentistry
Authors: Allen W. Hall
Journal: JAMA (1962)

The style of this textbook provides a practical approach to the enlightenment of those interested in all phases of dentistry for children. The material is arranged in an orderly and progressive manner, beginning with embryological development of the head, face, and oral cavity and ending with a short chapter on public health aspects of dentistry for children. Complete bibliographies are given after each chapter. The subject matter covers adequately the physical and pathological aspects encountered in dentistry for children but leaves one desirous of a more practical approach for dealing with the psychological problems which must be met. The chapters dealing with nutrition, dental caries, systemic diseases, and growth and development substantiate Dr. Cohen's effort toward the preventive approach and early recognition of disease. Dr. Cohen has succeeded in presenting a textbook which can be useful as a reference for medical colleagues and others in the allied health professions in
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
Authors: Evangelos J. Giamarellos-Bourboulis, Garyfallia Poulakou, Aline de Nooijer, Haralampos Milionis, Simeon Metallidis, Michalis Ploumidis, Pinelopi Grigoropoulou, Aggeliki Rapti, Francesco Vladimiro Segala, Evangelos Balis, Efthymia Giannitsioti, Paola Rodari, Ilias Kainis, Zoi Alexiou, Emanuele Focà, Brollo Lucio, Nikoletta Rovina, Laura Scorzolini, Maria Dafni, Sofia Ioannou, Alessandro Tomelleri, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Christina Trakatelli, George Tsoukalas, Carlo Selmi, Charilaos Samaras, Maria Saridaki, Athina Pyrpasopoulou, Elisabeth Kaldara, Ilias Papanikolaou, Aikaterini Argyraki, Karolina Akinosoglou, Marina Koupetori, Periklis Panagopoulos, George N. Dalekos, Mihai G. Netea
Journal: Cell Reports Medicine (2022)

Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms, but many develop severe symptoms associated with an excessive inflammatory response. Elevated plasma concentrations of soluble urokinase plasminogen activator receptor (suPAR) provide early warning of progression to severe respiratory failure (SRF) or death, but access to suPAR testing may be limited. The Severe COvid Prediction Estimate (SCOPE) score, derived from circulating concentrations of C-reactive protein, D- dimers, interleukin-6, and ferritin among patients not receiving non-invasive or invasive mechanical ventilation during the SAVE-MORE study, offers predictive accuracy for progression to SRF or death within 14 days comparable to that of a suPAR concentration of ≥6 ng/mL (area under receiver operator characteristic curve 0.81 for both). The SCOPE score is validated in two similar independent cohorts. A SCOPE score of 6 or more is an alternative to suPAR for predicting progression to SRF or death within 14 days of hospital admission for pneumonia, and it can be used to guide treatment decisions.
Physiology Of Thrombospondin
Authors: D. Mosher
Journal: Annual Review of Medicine (1990)

Thrombospondin is a large, multifunctional glycoprotein released from activated platelets and secreted by growing cells. It binds to components of the cell surface and extracellular milieu. Thrombospondin probably modulates a number of processes, including aggregation of platelets, formation and lysis of fibrin, adhesion and migration of cells, and progression of cells through the growth cycle. Studies relating thrombospondin to disease processes are just beginning.
Phthirus pubis infestation of the eyelashes
Authors: J. O. Alexander
Journal: JAMA (1983)

<h3>In Reply.—</h3> Drs Bell and Tubbs raise a matter of concern to those who cannot reconcile the process of evolution with their religious convictions. While I appreciate that concern, I must reiterate that new genetic studies strongly buttress the mass of evidence favoring evolution and the continuous nature of the species. Indeed, they delineate some of the genetic mechanisms by which evolution occurs. Even the continuing appearance of mutations in human populations, for example, the hemoglobin S allele with its associated positive and negative selective values, edges us along an evolutionary pathway and indicates that that process is not over. The paleontologic studies and amino acid sequence comparisons referred to by Drs Bell and Tubbs are valuable but crude tools by today's molecular genetic standards. They nevertheless pointed us in the right direction. Evolution and the continuity of life are scientific facts with which Drs Bell and Tubbs and those
Therese Neumann of Konnersreuth
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of Three Anorexiants
Authors: Michael H. M. Dykes
Journal: JAMA (1974)

Clortermine hydrochloride, fenfluramine hydrochloride, and mazindol are comparable to other anorexiants in suppressing the appetite. They should only be used as short-term adjuncts in a program that also includes caloric restriction, appropriate exercise, and psychologic support. Mazindol is the only anorexiant that is not a phenethylamine, and fenfluramine has the unusual property of producing both anorexia and central nervous system depression. (<i>JAMA</i>230:270-272, 1974)
Dissociation and Dissociative Disorders Reconsidered: Beyond Sociocognitive and Trauma Models Toward a Transtheoretical Framework
Authors: Steven Jay Lynn, Craig Polizzi, Harald Merckelbach, Chui-De Chiu, Reed Maxwell, Dalena van Heugten, Scott O. Lilienfeld
Journal: Annual Review of Clinical Psychology (2022)

For more than 30 years, the posttraumatic model (PTM) and the sociocognitive model (SCM) of dissociation have vied for attention and empirical support. We contend that neither perspective provides a satisfactory account and that dissociation and dissociative disorders (e.g., depersonalization/derealization disorder, dissociative identity disorder) can be understood as failures of normally adaptive systems and functions. We argue for a more encompassing transdiagnostic and transtheoretical perspective that considers potentially interactive variables including sleep disturbances; impaired self-regulation and inhibition of negative cognitions and affects; hyperassociation and set shifts; and deficits in reality testing, source attributions, and metacognition. We present an overview of the field of dissociation, delineate uncontested and converging claims across perspectives, summarize key multivariable studies in support of our framework, and identifyempirical pathways for future research to advance our understanding of dissociation, including studies of highly adverse events and dissociation.
Signal Transducer and Activator of Transcription (STAT)-A and STAT5B Differentially Regulate Human Mammary Carcinoma Cell Behavior
Authors: Jian-Zhong Tang, Ze-Hua Zuo, Xiang-Jun Kong, Michael Steiner, Zhinan Yin, Jo K. Perry, Tao Zhu, Dong-Xu Liu, Peter E. Lobie
Journal: Endocrine Reviews (2009)

Abstract Increased signal transducer and activator of transcription (STAT)-5 activation has been reported in various malignancies including mammary carcinoma. However, it is only recently that potentially distinct roles of STAT5A and STAT5B in neoplasia have begun to emerge. Herein we systematically delineate the functions of STAT5A and STAT5B in human mammary carcinoma cells. Forced expression of constitutively active (CA) STAT5A enhanced both survival and anchorage-independent growth of human mammary carcinoma cells but concordantly suppressed cell motility as revealed in colony scattering, cell migration, and invasion assays. In contrast, forced expression of CA STAT5B exhibited lower potency than CA STAT5A in enhancing survival and anchorage-independent growth of mammary carcinoma cells and exerted no effects on cell motility. Differential expression of genes that regulate cellular survival and motility was concomitantly observed on forced expression of CA STAT5A or CA STAT5B. We also observed that functions of STAT5A and STAT5B were similarly differential in T47D cells. Small interfering RNA-mediated depletion of STAT5A significantly impaired anchorage-independent growth of MCF-7 cells, whereas a smaller reduction was observed upon small interfering RNA-mediated depletion of STAT5B. Depletion of endogenous STAT5A also significantly enhanced cell motility, whereas depletion of endogenous STAT5B exhibited no effect. Xenograft studies provided data concordant with the in vitro effects of the two STAT5 isoforms. We therefore demonstrate that STAT5A and STAT5B differentially regulate behavior of human mammary carcinoma cells.
BUDAPEST
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LAW &amp; MEDICINE
Authors: Angela Roddey Holder
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Remarks of the AMA president
Authors: M. O. Rouse
Journal: JAMA (1968)

Each year at the opening session of the annual convention of the American Medical Association, it is the responsibility and privilege of the current President to offer a final report to the House of Delegates. Each man who stands in this honored place chooses the format for his own retiring address. The one I have chosen is a look at the year through which we have just come, then a short analysis of the present, followed by a brief examination of what we might expect in the years ahead. First, may I express our deep, heartfelt gratitude and appreciation for the many courtesies extended to Mrs. Rouse and me as we have had the privilege of visiting in practically every state of our great nation. The support of thousands of dedicated physicians and their wives has meant everything to us. Particularly would I also like to thank the members of
Association News.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal